SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 93.47 Billion KRW | -20.72% |
| 2022 | 117.91 Billion KRW | -18.93% |
| 2021 | 145.45 Billion KRW | -18.62% |
| 2020 | 178.72 Billion KRW | 6.05% |
| 2019 | 168.53 Billion KRW | 4.91% |
| 2018 | 160.64 Billion KRW | 4.18% |
| 2017 | 154.19 Billion KRW | 11.5% |
| 2016 | 138.28 Billion KRW | 6.2% |
| 2015 | 130.21 Billion KRW | 126.82% |
| 2014 | 57.41 Billion KRW | -28.4% |
| 2013 | 80.17 Billion KRW | -22.17% |
| 2012 | 103.01 Billion KRW | 17.7% |
| 2011 | 87.52 Billion KRW | 11.26% |
| 2010 | 78.66 Billion KRW | 8.53% |
| 2009 | 72.48 Billion KRW | 11.87% |
| 2008 | 64.79 Billion KRW | 27.06% |
| 2007 | 50.99 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 131.43 Billion KRW | 40.61% |
| 2024 Q2 | 119.43 Billion KRW | -9.13% |
| 2023 Q1 | 117.15 Billion KRW | -0.64% |
| 2023 Q4 | 93.47 Billion KRW | -9.63% |
| 2023 Q3 | 103.43 Billion KRW | -7.92% |
| 2023 FY | 93.47 Billion KRW | -20.72% |
| 2023 Q2 | 112.34 Billion KRW | -4.11% |
| 2022 Q3 | 128.95 Billion KRW | -2.58% |
| 2022 FY | 117.91 Billion KRW | -18.93% |
| 2022 Q4 | 117.91 Billion KRW | -8.56% |
| 2022 Q1 | 137.81 Billion KRW | -5.26% |
| 2022 Q2 | 132.37 Billion KRW | -3.95% |
| 2021 Q4 | 145.45 Billion KRW | -6.28% |
| 2021 Q3 | 155.19 Billion KRW | -4.58% |
| 2021 Q2 | 162.64 Billion KRW | -1.89% |
| 2021 Q1 | 165.77 Billion KRW | -7.25% |
| 2021 FY | 145.45 Billion KRW | -18.62% |
| 2020 Q3 | 180.73 Billion KRW | -0.59% |
| 2020 Q1 | 184.97 Billion KRW | 0.0% |
| 2020 Q2 | 181.8 Billion KRW | -1.71% |
| 2020 Q4 | 178.72 Billion KRW | -1.11% |
| 2020 FY | 178.72 Billion KRW | 6.05% |
| 2019 FY | 168.53 Billion KRW | 4.91% |
| 2019 Q1 | 165.86 Billion KRW | 3.25% |
| 2019 Q2 | 165.19 Billion KRW | -0.4% |
| 2019 Q3 | 158.65 Billion KRW | -3.96% |
| 2018 Q1 | 158.9 Billion KRW | 3.05% |
| 2018 Q4 | 160.64 Billion KRW | -5.39% |
| 2018 Q2 | 169.21 Billion KRW | 6.49% |
| 2018 FY | 160.64 Billion KRW | 4.18% |
| 2018 Q3 | 169.8 Billion KRW | 0.35% |
| 2017 FY | 154.19 Billion KRW | 11.5% |
| 2017 Q4 | 154.19 Billion KRW | 9.63% |
| 2017 Q3 | 140.65 Billion KRW | -1.41% |
| 2017 Q2 | 142.66 Billion KRW | 4.8% |
| 2017 Q1 | 136.13 Billion KRW | -1.55% |
| 2016 FY | 138.28 Billion KRW | 6.2% |
| 2016 Q4 | 138.28 Billion KRW | -14.88% |
| 2016 Q3 | 162.45 Billion KRW | 29.78% |
| 2016 Q2 | 125.17 Billion KRW | -6.1% |
| 2016 Q1 | 133.3 Billion KRW | 2.37% |
| 2015 Q2 | 94.08 Billion KRW | 0.0% |
| 2015 Q3 | 109.63 Billion KRW | 16.53% |
| 2015 Q4 | 130.21 Billion KRW | 18.78% |
| 2015 FY | 130.21 Billion KRW | 126.82% |
| 2014 FY | 57.41 Billion KRW | -28.4% |
| 2014 Q4 | 57.41 Billion KRW | 0.0% |
| 2014 Q1 | 77.95 Billion KRW | -2.78% |
| 2013 FY | 80.17 Billion KRW | -22.17% |
| 2013 Q4 | 80.17 Billion KRW | -17.91% |
| 2013 Q3 | 97.67 Billion KRW | -4.44% |
| 2013 Q2 | 102.21 Billion KRW | 5.31% |
| 2013 Q1 | 97.05 Billion KRW | -5.78% |
| 2012 Q1 | 94.59 Billion KRW | 8.08% |
| 2012 Q2 | 91.26 Billion KRW | -3.52% |
| 2012 Q3 | 94.34 Billion KRW | 3.38% |
| 2012 Q4 | 103.01 Billion KRW | 9.19% |
| 2012 FY | 103.01 Billion KRW | 17.7% |
| 2011 Q4 | 87.52 Billion KRW | -0.67% |
| 2011 Q2 | 88.96 Billion KRW | 3.9% |
| 2011 Q1 | 85.62 Billion KRW | 8.84% |
| 2011 Q3 | 88.11 Billion KRW | -0.95% |
| 2011 FY | 87.52 Billion KRW | 11.26% |
| 2010 Q2 | 77.15 Billion KRW | 5.08% |
| 2010 Q3 | 78.18 Billion KRW | 1.33% |
| 2010 Q4 | 78.66 Billion KRW | 0.62% |
| 2010 Q1 | 73.42 Billion KRW | 1.29% |
| 2010 FY | 78.66 Billion KRW | 8.53% |
| 2009 Q3 | 71.9 Billion KRW | 7.72% |
| 2009 Q1 | 66.83 Billion KRW | 3.14% |
| 2009 Q4 | 72.48 Billion KRW | 0.81% |
| 2009 Q2 | 66.75 Billion KRW | -0.12% |
| 2009 FY | 72.48 Billion KRW | 11.87% |
| 2008 Q2 | 50.4 Billion KRW | 2.91% |
| 2008 Q3 | 49.82 Billion KRW | -1.16% |
| 2008 Q4 | 64.79 Billion KRW | 30.05% |
| 2008 FY | 64.79 Billion KRW | 27.06% |
| 2008 Q1 | 48.97 Billion KRW | -3.96% |
| 2007 Q3 | 50.9 Billion KRW | -1.65% |
| 2007 FY | 50.99 Billion KRW | 0.0% |
| 2007 Q4 | 50.99 Billion KRW | 0.19% |
| 2007 Q1 | 50.2 Billion KRW | 0.0% |
| 2007 Q2 | 51.75 Billion KRW | 3.1% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 52.839% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 95.224% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 89.341% |
| HANDOK Inc. | 790.33 Billion KRW | 88.172% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | 45.212% |
| Yuhan Corporation | 2814.07 Billion KRW | 96.678% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 92.893% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 95.211% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 61.009% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 80.064% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | 18.695% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | 60.482% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 73.168% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 52.839% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 77.7% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 81.296% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 84.14% |
| JW Holdings Corporation | 1176.26 Billion KRW | 92.053% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 84.707% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 93.334% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 85.508% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 73.298% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | 39.316% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 74.782% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 80.818% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 52.839% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 91.329% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 94.72% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 85.508% |
| Yuhan Corporation | 2814.07 Billion KRW | 96.678% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 89.377% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | 58.747% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 90.593% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 85.508% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 77.738% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 80.063% |
| CKD Bio Corp. | 293.78 Billion KRW | 68.181% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 81.599% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 83.454% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 76.702% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 73.298% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 93.58% |
| Boryung Corporation | 922.36 Billion KRW | 89.865% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 78.873% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 80.064% |
| JW Lifescience Corporation | 255.83 Billion KRW | 63.461% |